Anthropic is entering the drug discovery space with a new artificial intelligence program aimed at finding treatments for diseases that receive little attention from the pharmaceutical industry. The initiative marks the company’s latest move to expand its AI business beyond software and into healthcare, where several major technology firms are already competing.
Speaking at an event in San Francisco, Anthropic’s head of life sciences, Eric Kauderer-Abrams, said the company wants to gain firsthand experience in drug development while building AI tools for researchers and pharmaceutical companies. He explained that working directly on drug discovery would help Anthropic better understand the challenges scientists face and improve the products it creates for the industry.
The company plans to focus on neglected diseases that often receive limited investment because they are considered less commercially attractive. Anthropic has not revealed what it would do if its research identifies promising drug candidates, though such discoveries would normally move into clinical testing before reaching patients. A company spokesperson said the program reflects Anthropic’s goal of supporting projects based on patient benefit rather than commercial potential alone.
The move places Anthropic alongside other technology companies that have invested heavily in healthcare. While firms such as Alphabet, Apple, and Amazon have expanded into the sector through different strategies, Anthropic hopes its growing portfolio of AI tools will help strengthen partnerships with life sciences companies while advancing research into overlooked diseases.
Related Readings:
